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Abstract
Background: High rates of bacterial coinfection in autopsy data from the 2009 H1N1 influenza (“flu”) pandemic
suggest synergies between flu and pneumococcal disease (PD) during pandemic conditions, and highlight the
importance of interventions like the 13-valent pneumococcal conjugate vaccine (PCV13) that may mitigate the
impact of a pandemic.
Methods: We used a decision-analytic model, estimated from published sources, to assess the impact of
pediatric vaccination with PCV13 versus the 7-valent vaccine (PCV7) on PD incidence and mortality in a
normal flu season (10% flu incidence) and in a pandemic similar to 2009-2010 H1N1 (20% flu incidence,
mild virulence, high impact in children). Both direct and indirect (herd) effects against PD were considered.
Effectiveness of PCV13 was extrapolated from observed PCV7 data, using assumptions of serotype prevalence
and PCV13 protection against the 6 serotypes not in PCV7. To simulate 2009–2010 H1N1, autopsy data were
used to estimate the overall proportion of flu deaths withb a c t e r i a lc o i n f e c t i o n s .B y assuming that increased
risk of death during the pandemic occurred among those with comorbidity (using obesity as proxy) and
bacterial coinfections primarily due to S. pneumoniae or S. aureus, we estimated the proportion co-infected
among all (fatal and non-fatal) flu cases (7.6% co-infected with any organism; 2.2% with S. pneumoniae). PD
incidence, mortality, and total healthcare costs were evaluated over a 1-year horizon.
Results: In a normal flu season, compared to PCV7, PCV13 is expected to prevent an additional 13,400
invasive PD (IPD) cases, 399,000 pneumonia cases, and 2,900 deaths, leading to cost savings of $472 M. In a
pandemic similar to 2009–2010 H1N1, PCV13 would prevent 22,800 IPD cases, 872,000 pneumonia cases, and
3,700 deaths, resulting in cost savings of $1.0 B compared to PCV7.
Conclusions: In a flu pandemic similar to the 2009–2010 H1N1, protection against the 6 additional
serotypes in PCV13 would likely be effective in preventing pandemic-related PD cases, mortality, and
associated costs.
Keywords: Pneumococcal disease, Influenza, H1N1 pandemic
Background
The 1918 influenza pandemic resulted in at least 20
million deaths worldwide, with some estimates as
high as 100 million [1-4]. Over the succeeding de-
cades, considerable efforts have been made to deter-
mine why mortality during the 1918 pandemic was
so high and ensure that such a catastrophic outcome
c o u l db ea v o i d e di nf u t u r ep a n d e m i c s .A tt h et i m eo f
the pandemic, researchers suspected complications of
bacterial pneumonia as the primary driver of excess
influenza deaths [5]. This theory has recently gained
support from autopsy studies of 1918 influenza vic-
tims that have established a link between secondary
bacterial infection and death by confirming the pres-
ence of bacterial pneumonia in nearly all autopsy
samples examined [6,7].
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declared the novel influenza A H1N1 virus A/California/
7/2009 (referred to as 2009–2010 H1N1) as a pan-
demic, making it the world’sf o u r t hi n f l u e n z ap a n -
d e m i ci nt h el a s tc e n t u r ya n dt h ef i r s ti n4 0y e a r s[ 8 ] .
By November 2009, WHO reported more than one-
half million confirmed novel H1N1 influenza cases
and more than six thousand deaths [9]. Several stud-
ies of H1N1-infected patients worldwide have con-
firmed high levels of bacterial coinfection, and there
is evidence to suggest that bacterial coinfection led to
excess H1N1 deaths. A retrospective analysis of hospi-
talized patients with laboratory-confirmed H1N1 in
Malaysia found 14 of 50 patients (28%) to have a bac-
terial coinfection [10], and in a study of 199 H1N1-
infected patients in Argentina, S. pneumoniae was
detected in 56% of the 39 H1N1 cases that resulted in
hospitalization or death [11]. An autopsy study in
Brazil found bacterial coinfection in 8 of 21 (38%)
samples [12], an autopsy study of H1N1 victims in
New York City confirmed the presence of bacterial
pneumonia in 18 of 33 (55%) samples examined for
pulmonary bacterial infection [13], and a Centers for
Disease Control and Prevention (CDC) H1N1 autopsy
s t u d yr e p o r t e de v i d e n c eo fb a c t e r i a li n f e c t i o ni n2 2o f
77 (29%) samples [14].
The synergies observed between bacterial pneumonia
and influenza with respect to morbidity and death dur-
ing influenza pandemics suggest pediatric pneumococcal
vaccination may mitigate the public health impact of an
influenza pandemic by preventing bacterial coinfections
with S. pneumoniae [15]. Since approval of the 7-valent
pneumococcal conjugate vaccine (PCV7) in 2000 for
pediatric use in children aged up to 59 months [16],
PCV7 has resulted in a marked reduction in the inci-
dence of invasive pneumococcal disease (IPD) [17-19]
and pneumonia [20] in both the vaccinated and non-
vaccinated populations (i.e. due to indirect protection).
In a previously published study, we estimated that a
fully-implemented PCV7 pediatric vaccination program
would avoid 1.2 million cases of IPD and pneumonia
and save $7.3 billion in a pandemic of similar severity to
1918 [15].
In 2010, the 13-valent pneumococcal conjugate
vaccine (PCV13) replaced PCV7 as the recommended
pediatric pneumococcal vaccine [21]. PCV13 is more
expensive than PCV7, but protects against the seven
serotypes covered by PCV7 plus an additional six se-
rotypes, including 19A. PCV13 vaccination was not
in place during the 2009–2010 influenza season, and
the possible benefits of the vaccine in a pandemic of
this magnitude are unknown. The current study ex-
plores the impact of vaccinating children against the
additional six serotypes in PCV13 both during a normal
influenza season and during a pandemic similar to the
2009–2010 H1N1.
Methods
Overview
In a previously-published study, we constructed a
decision-analytic model to assess the impact of pediatric
PCV7 vaccination versus a policy of no PCV vaccin-
ation in the context of an influenza pandemic of
1918 severity [15]. That model was updated to assess
the impact of pediatric PCV13 vaccination versus
continued vaccination with PCV7 during a normal
season [22] and influenza pandemic of 1918 severity
(unpublished analysis). For the current analysis, the
model was adapted to assess the impact of pediatric
PCV13 vaccination versus continued vaccination with
PCV7 during an influenza pandemic similar to the
2009–2010 H1N1. Clinical and economic outcomes
related to IPD (meningitis and bacteremia) and all-
cause pneumonia were evaluated over a 1-year time
horizon to reflect one influenza season, and long-
term outcomes of events occurring during the one-
year period were projected to the lifetime of the
model population. Future costs and health outcomes
attributable to cases occurring in the index year were
discounted to present values using a 3% annual dis-
count rate [23].
The model considers outcomes of pneumococcal
disease only; morbidity, mortality, and costs of influ-
enza without pneumococcal coinfection were assumed
to be unaffected by pneumococcal vaccination and are
not considered. Outcomes include cases of pneumo-
coccal disease, pneumococcal-associated deaths, and
related costs. In all analyses, we compared a policy of
pediatric PCV13 vaccination to one of pediatric PCV7
vaccination in populations with fully-implemented vac-
cine programs.
Estimation
Pneumococcal disease incidence and mortality, and vaccine
efficacy
Estimates of vaccine coverage, pneumococcal disease in-
cidence and mortality, and vaccine effectiveness have
been previously published in a study of the public health
and economic impact of PCV13 in the United States
(see Appendix) [22]. Briefly, age-specific pneumococ-
cal disease incidence and mortality rates were esti-
mated from Active Bacterial Core Surveillance (ABCs)
data [17,24-26] and other published observational
studies [20,27-34]. Direct efficacy and expected indir-
ect effects were estimated from published and unpub-
lished age- and serotype-specific data from the ABCs
and other published sources [20,24,25,34-38]. Esti-
mates of vaccine efficacy for children aged 2-4 years
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cine. Indirect effects represent the expected benefit to
older children and adults from a fully implemented
vaccination program (approximately seven years post-
vaccine introduction).
Influenza incidence
We estimated the influenza incidence in a pandemic
similar to the 2009–2010 H1N1 from data published
by the CDC. According to CDC estimates, approxi-
mately 61 million US residents were infected with
H1N1 during the 2009–2010 influenza season, indi-
cating a cumulative incidence of 20% in a population
of approximately 300 million [39]. We estimated age-
specific incidence of influenza using data from a study
that predicted the true prevalence of H1N1 based on
laboratory-confirmed specimens and modeling tech-
niques [40]. We applied the age-specific odds ratios
calculated from the prevalence study to the CDC esti-
mates of influenza incidence to arrive at influenza in-
cidence estimates of 44.3% for children aged 0–4
years, 51.7% for the 5–17 years age group, 13.5% for
the 18–49 years age group, 7.6% for the 50–64 years
age group, and 2.5% for those aged 65+ years. The
CDC estimates that approximately 12,470 deaths were
associated with the 2009–2010 H1N1, indicating a
case-fatality of approximately 0.2% [39].
Pneumococcal disease incidence and mortality in
a pandemic
Data on pneumococcal disease incidence during the
2009–2010 H1N1 pandemic are limited. To estimate
the incidence of pneumococcal disease and simulate the
potential acceleration of pneumococcal disease trans-
mission in a pandemic similar to the 2009–2010 H1N1,
we estimated the proportion of influenza cases with
bacterial coinfection [14]. Autopsy data were available
to estimate the proportion of influenza deaths with
bacterial coinfection, from which the proportion of
coinfection among all H1N1 cases (i.e., both fatal and
non-fatal) was derived.
Because the proportion of influenza deaths with co-
infection at autopsy is driven both by rates of coin-
fection and excess mortality due to coinfection, a
number of assumptions were necessary to estimate
the rate of coinfection among all H1N1 cases. First,
we assumed that the underlying increased risk of
death due to influenza among those with comorbid-
ity, using obesity as a proxy, was unrelated to coin-
fection. Second, we assumed that the excess risk of
death due to coinfection during the pandemic was
equal among those with and without comorbidity.
These two assumptions imply that there are no syn-
ergies between comorbidity and coinfection with
respect to mortality. Third, we assumed that obesity
is not associated with risk of influenza or coinfection,
such that the prevalence of obesity and morbid obes-
ity among those with influenza is expected to be the
same as that in the U.S. population. We further as-
sumed that bacterial coinfections were primarily due
to S. pneumoniae or S. aureus. Details regarding the
equations used to estimate the probability of coinfec-
tion are provided in the Appendix. In summary, we
derived the following equation for the proportion of
H1N1 cases co-infected:
γ ¼ Fc 1 þ Po RRo−1 ðÞ þ Pb RRb−1 ðÞ −1 ½  fg =
Po RRo−1 ðÞ þ Pb RRb−1 ðÞ fg
where γ is the probability of bacterial coinfection
with any organism among all influenza patients, Fc is
the fraction of deaths from bacterial coinfection with
any organism, Po is the prevalence of obesity, Pb is
t h ep r e v a l e n c eo fm o r b i do b e s i t y ,R R o is the risk ra-
tio for influenza-related death for those obese versus
normal weight, and RRb is the risk ratio for influenza-
related death for those morbidly obese versus normal
weight.
Based on pediatric autopsy data from the CDC, we
assumed that 43% of patients dying from 2009–2010
H1N1 influenza were co-infected with any bacterial
organism (Fc), and that 30% of patients with any bac-
terial coinfection were co-infected with S. pneumoniae
[41]. We estimated the relative risk of death for obese
(RRo:3 . 1 )a n dm o r b i d l yo b e s e( R R b: 7.6) individuals
compared to individuals of normal weight from a
case-cohort study of patients hospitalized during the
2009–2010 H1N1 pandemic [42]. Based on obesity
data from the National Health and Nutrition Examin-
ation Survey (NHANES), we assumed 33.8% of the
adult population in the United States to be obese
(body mass index [BMI] ≥ 30) and 20% of the obese
population to be morbidly obese (BMI ≥ 40) [43]. We
then solved for the proportion of all H1N1 influenza
patients who also had a bacterial coinfection, resulting
in estimates of 7.6% of patients with any bacterial
coinfection and 2.2% of patients co-infected with
S. pneumoniae. We used the same model to estimate
the risk of bacterial coinfection in a normal influenza
season (1.5%). The multiplier on pneumococcal disease
incidence during a pandemic influenza season of 5.01
was calculated as the ratio of the pandemic- versus
normal-season prevalence of coinfection.
It was assumed that background pneumococcal dis-
ease incidence and mortality, as described above in
the section on “Pneumococcal Disease Incidence and
Mortality, and Vaccine Efficacy”,r e p r e s e n tt h ea c t u a l
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enza season and therefore any synergies between
pneumococcal disease and influenza would be cap-
t u r e di nt h eo b s e r v e di n c i d e n c e .T h e r e f o r e ,w ed i d
not make any additional assumptions about synergies
between influenza and pneumococcal disease when
estimating the model for a normal influenza season.
Costs and utilities
All pneumococcal disease costs were estimated from
published sources as described previously; to maintain
consistency with previous analyses, costs are in $2008
US [22].Briefly, costs associated with non-hospitalized
pneumonia for children aged <5 years and IPD and
hospitalized pneumonia for all ages were adapted
from Ray et al., 2009 [44]. Costs of long-term conse-
quences of meningitis were adapted from lifetime
costs of deafness and disability for children <5 years
and adjusted by discounted life-expectancy. Non-
hospitalized pneumonia costs for persons aged ≥5
years were estimated as the total of an office visit,
chest radiograph, blood culture, and one course of
antibiotics [22].
The costs used for PCV7 and PCV13 are consistent
with the prices at the time of PCV13 launch as used in
previous publications. The average cost for a single dose
of PCV13 in the US was assumed to be $100, while the
average cost for a single dose of PCV7 was assumed to
be $73 [22]. Both vaccines were assumed to have an ad-
ministration cost of $11 per dose [33].
Utilities, preference-based quality-of-life measures ran-
ging from 0 to 1, were incorporated by assigning a
quality-adjusted life-year (QALY) decrement for each
pneumococcal disease episode, as described previously
[22].Lifetime costs and consequences (including life-
years lost and permanent disabilities) attributable to a
case of IPD were discounted to present value at an an-
nual rate of 3%.
Analyses
The model generates estimates of pneumococcal dis-
ease cases avoided, deaths averted, cost differences,
and QALYs gained for a policy of PCV13 pediatric
vaccination versus a policy of PCV7 pediatric vaccin-
ation. Cases and deaths averted were calculated as
the difference in the total number of cases/deaths
with PCV13 pediatric vaccination minus the total
number of cases/deaths with PCV7 vaccination. Cost
differences were calculated by subtracting total costs
for a policy of PCV13 pediatric vaccination (the cost
of vaccinating children with PCV13 less any cost off-
sets associated with avoiding disease), from total
costs associated with a PCV7 pediatric vaccination
policy. Analyses were conducted under assumptions
meant to replicate the 2009-2010 H1N1 pandemic
and also under normal influenza conditions to serve
as a comparison to the pandemic. All results are
presented from the payer perspective, and therefore
consider only direct medical costs.
Direct and indirect effectiveness of PCV13 were es-
timated by extrapolating from the PCV7 experience,
so there is considerable uncertainty regarding the
expected benefits of PCV13 in unvaccinated popula-
tions. We therefore performed sensitivity analyses to
assess how changes in assumptions regarding indirect
effectiveness would change model results by, in turn,
assuming: 1) PCV13 vaccine has no indirect effect-
iveness against either IPD or pneumonia, 2) PCV13
vaccine has indirect effectiveness against IPD and
hospitalized pneumonia, but no indirect effectiveness
against non-hospitalized pneumonia, or 3) PCV13
vaccine has indirect effectiveness against IPD and
both hospitalized and non-hospitalized pneumonia.
Because our estimation of the prevalence of bacterial
co-infection was based on a number of assumptions,
we also performed a sensitivity analysis in which the
prevalence of co-infection was reduced by half.
Results
Base-case
The model predicts that 3.6 million children aged
birth to <1 year will receive the pneumococcal vaccine
over a 1-year time horizon; an additional 12.2 million
children aged 1-<5 years will receive direct protec-
tion from vaccination in prior years. In a normal
influenza season, the model predicts that with a
PCV7 pediatric vaccination program we would expect
40,800 cases of IPD and 4.52 million cases of all-
cause pneumonia; vaccinating children with PCV13
would reduce these numbers to 27,400 IPD cases and
4.12 million all-cause pneumonia cases. In a pandemic
similar to the 2009–2010 H1N1, a PCV7 pediatric
vaccination policy would lead to an expected 62,100
IPD cases and 9.95 million all-cause pneumonia cases.
A policy of PCV13 vaccination reduces this to 39,300
cases of IPD and 9.08 million cases of all-cause
pneumonia. Table 1 displays the numbers of add-
itional cases of pneumococcal disease avoided with
PCV13 versus PCV7, by age group, for both influ-
enza scenarios.
In a normal influenza season, PCV13 is expected to
prevent an estimated 2,900 deaths compared to PCV7;
4,200 IPD and 23,200 hospitalized pneumonia deaths are
expected with PCV7, while 3,000 IPD and 21,500 hos-
pitalized pneumonia deaths are expected with PCV13.
For a pandemic similar to 2009–2010 H1N1, PCV13
is expected to prevent an estimated 3,700 deaths com-
pared to PCV7; 5,400 IPD and 27,300 hospitalized
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with 3,800 IPD and 25,200 hospitalized pneumonia
deaths for PCV13. The numbers of pneumococcal
deaths averted for IPD and hospitalized pneumonia
for each influenza scenario are presented in Figure 1
(note: discrepancies in the difference calculations are
due to rounding).
Vaccination program costs are estimated at $1.1 billion
for PCV7 and $1.5 billion for PCV13. In a normal influ-
enza season, pneumococcal disease costs associated with
the PCV7 and PCV13 vaccination policies are $7.8
billion and $7.0 billion, respectively. For a pandemic
similar to 2009–2010 H1N1, PCV7 and PCV13 vac-
cination programs are projected to result in pneumo-
coccal disease costs of $12.7 billion and $11.3 billion,
respectively. The breakdown of medical cost savings
due to vaccination with PCV13, by presentation of
pneumococcal disease, is presented in Table 2 for both
influenza scenarios.
Sensitivity analyses
Assuming indirect protection against IPD and no in-
direct protection against all-cause pneumonia, PCV13
vaccination continues to result in significant cost sav-
ings compared to PCV7, for both a normal influenza
season and an influenza pandemic season similar to
2009-2010 H1N1. For a pandemic season, if PCV13 is
assumed to offer indirect protection only against IPD
but not all-cause pneumonia, medical cost savings
due to fewer cases of pneumococcal disease neverthe-
less more than offset the incremental cost of the
PCV13 vaccination program compared to PCV7. The
cost of the PCV13 vaccination program in a normal
influenza season is not entirely offset by medical cost
savings under the assumptions of no indirect protec-
tion against pneumonia; however, PCV13 vaccination
remains cost-effective compared with PCV7 vaccin-
ation at a cost of $4,300 per QALY gained. Given the
uncertainty in the proportion of all H1N1 influenza
patients who also had a bacterial coinfection, the
base-case assumption was halved, resulting in a multi-
plier of 2.5 on pneumococcal disease incidence during
a pandemic influenza season. The cost savings associated
with the PCV13 vaccination program under this scenario
were approximately two-thirds that of the cost savings in
the base case. The results of the sensitivity analyses are
presented in Table 3.
Discussion
High rates of bacterial coinfection in autopsy data from
the 2009–2010 H1N1 influenza pandemic suggest syn-
ergies between influenza and pneumococcal disease in
pandemic conditions. While influenza vaccination re-
mains the primary tool to control the significant bur-
den of influenza during both seasonal epidemics and
Table 1 Pneumococcal cases avoided with PCV13 vs. PCV7 pediatric vaccination in normal and pandemic influenza seasons
Normal influenza season
0-1 yrs 2-4 yrs 5-17 yrs 18-49 yrs 50-64 yrs 65+ yrs Total
IPD 1,900 1,100 400 3,600 2,500 3,800 13,400
Hospitalized pneumonia 10,000 2,000 3,600 17,500 2,800 22,000 57,400
Non-Hospitalized pneumonia 87,900 34,300 76,400 97,600 12,000 33,000 341,200
Total 99,300 37,400 80,500 118,700 17,300 58,900 412,000
Pandemic similar to 2009–2010 H1N1
0-1 yrs 2-4 yrs 5-17 yrs 18-49 yrs 50-64 yrs 65+ yrs Total
IPD 5,300 3,100 1,400 5,500 3,300 4,200 22,800
Hospitalized pneumonia 26,400 5,500 11,100 27,000 3,600 24,200 97,700
Non-Hospitalized pneumonia 242,500 94,500 234,600 150,300 15,700 36,300 773,800
Total 274,200 103,100 247,000 182,800 22,600 64,800 894,300
IPD, Invasive pneumococcal disease.
1,200
1,700
1,600
2,100
IPD Hospitalized pneumonia
Normal season Pandemic similar to 2009-2010 H1N1 
Figure 1 Pneumococcal deaths averted for PCV13 vs. PCV7
pediatric vaccination in normal and pandemic
influenza seasons.
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the potential to mitigate the impact of pandemic in-
fluenza. During the 2009–2010 H1N1 pandemic, pro-
tection against the six additional serotypes in PCV13
compared to PCV7 likely would have prevented a portion
of the pandemic-related pneumococcal cases, deaths,
and costs.
In a typical influenza season, a PCV13 vaccination pol-
icy is expected to prevent an additional 13,400 IPD
cases, 399,000 all-cause pneumonia cases, and 2,900
deaths, leading to cost savings of $472 million when
compared to a PCV7 vaccination policy. We previously
estimated that the PCV7 vaccination program in the US
was cost saving for a normal influenza season, reducing
pneumococcal-related costs by $1.6 billion per year;
therefore the total cost savings of PCV13 versus a policy
of no pneumococcal vaccination can be estimated at
$2.4 billion per year. In a relatively mild pandemic simi-
lar to 2009–2010 H1N1, PCV13 is expected to prevent
22,800 IPD cases (1.7x normal season), 872,000 all-cause
pneumonia cases (2.2x normal season), 3,700 deaths,
and save $1.0 billion (2.2x normal season) compared to
PCV7.
Our study is subject to a number of limitations inherent
in the study design. First, the decision-analytic model is ne-
cessarily a highly simplified representation of the disease
transmission and outcomes of pneumococcal disease.
Although we accounted for some differences in treatment
and outcomes using age stratification, we recognize that
the U.S. population and healthcare delivery system are
highly heterogeneous and may not be well represented by
the relatively simple structure of this model. We also note
that data used to estimate vaccine effectiveness and out-
comes were derived and synthesized from a variety of
sources, and this process of selection and interpretation is
subject to bias. Although extensive sensitivity analyses to
evaluate the effect of alternative parameter choices on our
outcomes showed no change in the overall conclusions, we
Table 2 Cost savings for PCV13 vs. PCV7 pediatric vaccination in normal and pandemic influenza seasons
Influenza scenario IPD Hospitalized pneumonia Non-Hospitalized pneumonia Vaccination Total
Normal season $ 235 M $ 509 M $ 96 M ($ 367 M) $ 472 M
Pandemic similar to 2009–2010 H1N1 $ 358 M $ 812 M $ 213 M ($ 367 M) $ 1.02 B
IPD, Invasive pneumococcal disease; M, Million; B, Billion.
Table 3 Sensitivity analyses around indirect effectiveness of PCV13 and co-infection assumptions in normal and
pandemic influenza seasons
Normal season
Base-Case IPD indirect effects only No indirect effects Halve % with bacterial co-infection
Cases avoided
IPD 13,400 13,400 2,100 13,400
Hospitalized pneumonia 57,400 5,000 5,000 57,400
Non-Hospitalized pneumonia 341,200 62,300 62,400 341,200
Deaths averted 2,900 1,200 40 2,900
Cost /(savings) $ (472) M $ 82 M $ 299 M ($ 472 M)
QALYs gained 41,524 18,953 4,484 41,524
Cost per QALY gained dominant $4,300 $66,800 dominant
Pandemic similar to 2009–2010 H1N1
Base-Case IPD indirect effects only No indirect effects Halve % with bacterial co-infection
Cases avoided
IPD 22,800 22,800 5,700 16,900
Hospitalized pneumonia 97,700 13,700 13,900 72,600
Non-Hospitalized pneumonia 773,800 170,800 171,900 504,000
Deaths averted 3,700 1,600 110 3,200
Cost/(savings) ($ 1.02 B) ($ 130 M) $ 180 M ($ 676 M)
QALYs gained 51,637 25,671 4,844 44,023
Cost per QALY gained dominant dominant $37,100 dominant
IPD, Invasive pneumococcal disease; M, Million; B, Billion; QALY, Quality-adjusted life-year.
McGarry et al. BMC Infectious Diseases 2013, 13:229 Page 6 of 11
http://www.biomedcentral.com/1471-2334/13/229recognize that different assumptions may have yielded dif-
ferent results.
Costs used in this analysis were taken from published
data and standard sources; the extent to which they reflect
the true costs of administering medical care is unknown.
Furthermore, this study was conducted from a third-party
payer perspective rather than a societal perspective, and as
such does not include costs of pneumococcal disease re-
lated to lost productivity, caregiver time, transportation, or
other unreimbursed expenses. Inclusion of these costs pre-
sumably would have added substantially to the total cost
burden of pneumococcal disease and the potential cost sav-
ings with PCV13. In addition, the model was estimated
using U.S. data, and care should be used in generalizing our
results to other settings and populations.
Because the data available to estimate pneumococcal
coinfections were incomplete and based on autopsy data, a
number of assumptions were necessary to convert these es-
timates of pneumococcal infection among influenza deaths
to population estimates of coinfection. Although we
attempted to be conservative in our assumptions, there re-
mains a high level of uncertainty in these estimates. In par-
ticular, our calculations using obesity as a surrogate for all
comorbidity is a simplification, and may not reflect the
mechanism leading to excess deaths in groups such as
those with asthma or immunosuppression, and pregnant
women. Studies that examinedo b e s i t ya l o n gw i t ho t h e r
comorbidities as a risk factor for poor outcomes in H1N1
have shown obesity to be the strongest and most consistent
predictor. For example more than half of hospitalized
H1N1 cases in California observed between April and Au-
gust 2009 were obese and one-quarter morbidly obese [45],
a n do b e s i t yw a si d e n t i f i e da st h es t r o n g e s tp r e d i c t o ro f
death in an analysis of hospitalized H1N1 cases in the
United Kingdom (odds-ratio = 6.08; p = 0.01) [46]. We fur-
ther note, that Morgan and colleagues [42] estimated the
odds-ratios of death for obese and morbidly obese persons
versus normal weight persons among patients with chronic
medical conditions that are risk factors for poor influenza
outcomes (as identified by the Advisory Committee on
Immunization Practices [ACIP]) and among patients with
no chronic medical condition s .T h e yf o u n dt h eo d d so f
death to be significantly elevated only among obese and
morbidly obese persons without chronic medical condi-
tions; suggesting that the increased risk associated with co-
morbidity may be captured by the increase risk due to
obesity in patient with both conditions.
It is also possible that our assumption of independ-
ence between obesity/comorbidity and bacterial coin-
fection as causes of death in persons with influenza
is not valid. However, we note that there is consider-
able overlap in the comorbidities considered risk fac-
tors for both adverse pneumococcal disease outcomes
and adverse influenza outcomes by ACIP [21,47],
suggesting that these conditions associated with poor
influenza outcome also increase risk in the presence
of pneumococcal infection. If there are synergies be-
tween comorbidity and coinfection, as suggested by a
study in Malaysia [10], the rate of coinfection may
be overestimated; however we found that even when
we halved our estimate of the rate of coinfection,
vaccination remained cost-saving in an assumed pan-
demic similar to 2009–2010 H1N1.
Conclusion
Our model suggests that, had PCV13 vaccination
been implemented prior to the recent 2009-2010
H1N1 pandemic, the protection provided would have
prevented more than 3,500 deaths and saved $1.0 bil-
lion. Although the 2009-2010 H1N1 pandemic proved
to be far less severe than initial reports suggested, even
in a relatively mild pandemic similar to the 2009–2010
H1N1, protection against the six additional serotypes
in PCV13 would likely be effective in preventing
pandemic-related pneumococcal disease cases, mortal-
ity, and associated costs.
Appendix
This section contains detailed descriptions of model pa-
rameters (Table 4) as well as additional explanation
around the assumptions and methodology for calculating
probabilities of coinfection.
Calculation of Probability of Coinfection
Definition of variables:
γ=probability of coinfection (any organism)
Fc= fraction of deaths with coinfection (any organism)*
mc =mortality with coinfection, normal weight
mo = mortality with coinfection, obese
mb = mortality with coinfection, morbidly obese
RRo =relative risk for death, obese vs. normal weight *
RRb=relative risk for death, morbidly obese vs. normal
weight *
Po= prevalence of obesity *
Pb= prevalence of morbid obesity *
M =total mortality among flu infected
* denotes variables with known or estimated values
Assumptions:
1. All influenza deaths are attributable to either
obesity or coinfection.
2. In the absence of coinfection, obese and morbidly
obese persons have progressively greater mortality
than persons of normal weight.
3. Excess mortality owing to coinfection is the same
for obese and non-obese persons.
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Parameter Age group (years)
0- <2 2-4 5-17 18-49 50-64 65+
Annual non-pandemic baseline incidence rates / 100,000
a
Pneumococcal meningitis 3.54 0.98 0.27 0.71 1.37 2.39
Pneumococcal bacteremia 33.9 13.2 2.16 6.97 18.5 35.5
All-cause pneumonia 8,749 7,752 1,648 750 328 2,163
Percent of meningitis that results in deafness
b 13% 13% 6% 13% 13% 13%
Percent of meningitis that results in disability
b 7% 7% 5% 7% 7% 7%
Case-Fatality Rates
Pneumococcal meningitis
c 6.9% 4.0% 10.0% 10.4% 11.4% 23.8%
Pneumococcal bacteremia
c 0.9% 0.4% 4.2% 6.2% 11.3% 15.7%
All-cause hospitalized pneumonia
d 0.4% 0.2% 0.3% 1.2% 2.5% 6.3%
Direct effects (% reduction in disease at time of vaccination)
e
IPD 49.8% –– – – –
All-cause hospitalized pneumonia 16.2% –– – – –
vAll-cause non-hospitalized pneumonia 3.8% –– – – –
Indirect effects (% reduction in disease)
f
IPD 32.7% 39.4% 34.4% 34.5% 24.5% 27.4%
All-cause hospitalized pneumonia 22.5% 0.0% 9.2% 11.3% 8.7% 6.9%
All-cause non-hospitalized pneumonia 6.2% 0.0% 4.7% 5.9% 3.7% 3.4%
Direct Medical Costs ($2008)
Meningitis episode
g $17,048 $17,048 –– – –
Bacteremia episode
g $3,253 $3,253 –– – –
Cost of invasive disease episode
g –– $12,738 $17,956 $22,135 $17,216
Lifetime cost of deafness
h $96,788 $96,788 $91,663 $73,530 $48,435 $35,261
Lifetime cost of disability
h $499,409 $499,409 $472,965 $379,402 $249,915 $181,940
Hospitalized pneumonia episode
h $7,276 $7,276 $4,994 $9,248 $10,148 $9,872
Non-hospitalized pneumonia episode
i $233 $233 $308 $308 $308 $308
Vaccine Price (per dose)
PCV7 $73 –– – – –
PCV13 $100 –– – – –
Vaccine administration $11 –– – – –
QALY Inputs (all ages)
j,k Meningitis Bacteremia Hospitalized
Pneumonia
Non-Hospitalized
Pneumonia
Deafness
(utility)
Disability
(utility)
0.023 0.008 0.006 0.004 0.73 0.68
Note: Comprehensive information related to estimation and references is available in two previously published studies [15,22].
a. Incidence rate estimates assume a steady state utilizing 2007 as the baseline year. IPD incidence estimated from unpublished ABCs data provided by Matt
Moore [24]. Hospitalized pneumonia incidence estimated from Grijalva [20] with updated estimates for kids <5 years from January 16, 2010 issue of the MMWR.
Non-hospitalized pneumonia incidence estimated from analyses of National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical
Care Survey (NHAMCS) 2006 (U.S. Dept. of Health and Human Services, National Center for Health Statistics [27,28].
b. Estimated from Lieu [29] and Shepard [30].
c. Adapted from ABCs Report: Emerging Infections Program Network. Streptococcus pneumoniae 2007 and Tsai [32].
d. Fatality rates estimated from National Vital Statistics report [32]; converted to case-fatality rates by applying rate of death to incidence rates from Grijalva et al. [20].
e. IPD estimated from serotype coverage of PCV13 from ABCs data assuming 94% efficacy against those types. Hospitalized pneumonia adapted from PCV7 efficacy in
Black [35] adjusted for PCV13 serotype coverage. Non-hospitalized pneumonia adapted from PCV7 efficacy in Hansen [36] adjusted for PCV13 serotype coverage.
f. IPD estimated from serotype-specific prevalence from ABCs data. Pneumonia estimated using age-specific reductions in disease observed after the introduction
of PCV7 in 2000, adjusted by serotype coverage.
g. Estimates for all ages adapted from Ray et al. [44].
h. Estimated from Ray et al. [44] for children <5 years; adjusted by relative difference in discounted life expectancy to obtain lifetime costs for older age groups.
i. Estimates for <5 years adapted from Ray et al. [44]; estimates for >5 years assumes 1 physician visit, 46% of patients receive chest radiograph, blood count and
culture, and one course of zithromycin.
j. QALY decrements adapted from Melegaro and Edmunds [48], a cost-effectiveness study in England and Wales that synthesized estimates from various primary sources.
k. Utilities for chronic health states estimated from retrospective studies of meningococcal complications [49,50].
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either obesity or morbid obesity are additive.
5. The incidence of influenza and the prevalence of
coinfection among obese and morbidly obese
people are the same as for people of normal weight.
Risk of death
There are 6 groups: 3 obesity categories, each of
which can be co-infected or not. The overall prob-
ability of death is the weighted average over these 6
groups. Assume those with neither comorbidities nor
coinfections are not at risk of death:
M ¼ γ 1   Po   Pb ðÞ   mc þ γPo mc þ mo ðÞ þ γPb mc þ mb ðÞ
þ 1   γ ðÞ Pomo þ 1   γ ðÞ Pbmb
¼ γmc þ Pomo þ Pbmb
ð1Þ
Mortality with coinfection
Because we assume that mortality due to obesity is
additive to mortality due to coinfection, and that
mortality due to coinfection is independent of obes-
ity, the probability of death among persons with co-
i n f e c t i o ni sa sf o l l o w s :
A ¼ 1   Po   Po ðÞ   mc þ Po mc þ mo ðÞ þ Pb mc þ mb ðÞ
ð2Þ
Since the probability of coinfection is further assumed
to be independent of obesity status, the probability of
dying and being co-infected is γ*Α.
Fraction of deaths with coinfection
Fc ¼ γA=M
¼ γ mc   Pomo þ Pbmb ðÞ = γmc   Pomo þ Pbmb ðÞ
ð3Þ
Relative risk (RR) for death, obese vs. normal weight
RRo ¼ 1   γ ðÞ mo þ γ mo þ mc ðÞ ½  =γmc
¼ mo þ γmc ðÞ =γmc
ð4Þ
Relative risk for death, morbidly obese vs. normal weight
RRb ¼ 1   γ ðÞ mb þ γ mb þ mc ðÞ ½  =γmc
¼ mb þ γmc ðÞ =γmc
ð5Þ
Solution of equations (3)-(5):
γ ¼ Fc 1 þ Po RRo   1 ðÞ þ Pb RRb   1 ðÞ   1 ½    1 fg =
Po RRo   1 ðÞ þ Pb RRb   1 ðÞ fg
(Technical note: We have 3 equations (3)-(5), with 4 un-
knowns (γ,m b,m o,a n dm c), but mb,m o,a n dm c can only
be determined relative to each other – not absolutely -
from the data available.)
Calculation
Fc =.43
RRo =3.1
RRb =7.6
Po= 0.138
Pb= 0.2
γ any organism ðÞ ¼ 0:43 1 þ 0:138 ðÞ 2:1 ðÞ þ 0:2 ðÞ 6:6 ðÞ ½  −1 fg =
0:1:38 ðÞ 2:1 ðÞ 6:6 ðÞ fg
¼ 0:1222=1:6
¼ 0:0759
Assuming 30% are S. pneumoniae:
γ S: pneumoniae ðÞ ¼ 0:0759   :30 ¼ 0:0228
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